The Medical Letter
Treatment Guidelines
May 13, 2013 (Issue 1416)
  • Alogliptin (Nesina) for Type 2 Diabetes
  • Omalizumab (Xolair) for Chronic Urticaria
  • Ospemifene (Osphena) for Dyspareunia